Display options
Cite
Tanaka M, Takahashi S, Higashiura Y, et al. Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals. J Diabetes Investig. 2021;doi: 10.1111/jdi.13735.
Tanaka, M., Takahashi, S., Higashiura, Y., Sakai, A., Koyama, M., Saitoh, S., Shimamoto, K., Ohnishi, H., & Furuhashi, M. (2021). Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals. Journal of diabetes investigation, . https://doi.org/10.1111/jdi.13735
Tanaka, Marenao, et al. "Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals." Journal of diabetes investigation vol. (2021). doi: https://doi.org/10.1111/jdi.13735
Tanaka M, Takahashi S, Higashiura Y, Sakai A, Koyama M, Saitoh S, Shimamoto K, Ohnishi H, Furuhashi M. Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals. J Diabetes Investig. 2021 Dec 09; doi: 10.1111/jdi.13735. Epub 2021 Dec 09. PMID: 34889064.
Copy Download .nbib Format: NLM
Share it on

J Diabetes Investig. 2021 Dec 09; doi: 10.1111/jdi.13735. Epub 2021 Dec 09.

Circulating level of fatty acid-binding protein 4 is an independent predictor of metabolic dysfunction-associated fatty liver disease in middle-aged and elderly individuals.

Journal of diabetes investigation

Marenao Tanaka, Satoko Takahashi, Yukimura Higashiura, Akiko Sakai, Masayuki Koyama, Shigeyuki Saitoh, Kazuaki Shimamoto, Hirofumi Ohnishi, Masato Furuhashi

Affiliations

  1. Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo, Japan.
  2. Department of Public Health, Sapporo Medical University School of Medicine, Sapporo, Japan.
  3. Department of Nursing, Division of Medical and Behavioral Subjects, Sapporo Medical University School of Health Sciences, Sapporo, Japan.
  4. Japan Health Care College, Sapporo, Japan.

PMID: 34889064 DOI: 10.1111/jdi.13735

Abstract

AIMS/INTRODUCTION: Metabolic dysfunction-associated fatty liver disease (MAFLD), defined as hepatosteatosis with type 2 diabetes mellitus, overweight/obesity or metabolic dysregulation, has been proposed as a new feature of chronic liver disease. Fatty acid-binding protein 4 (FABP4) is expressed in adipose tissue, and secreted FABP4 is associated with the development of insulin resistance and atherosclerosis. However, the relationship between MAFLD and FABP4 has not been fully addressed.

MATERIALS AND METHODS: Associations of MAFLD with metabolic markers, including FABP4, fibroblast growth factor 21 and adiponectin, were investigated in 627 individuals (men/women 292/335) in the Tanno-Sobetsu Study, a population-based cohort.

RESULTS: The mean age was 65 years (range 19-98 years, median [interquartile range] 68 [56-76] years). Hepatosteatosis was determined by the fatty liver index (FLI), and FLI ≥35 for men and FLI ≥16 for women were used for detection of fatty liver, as previously reported using 14,471 Japanese individuals. FLI was positively correlated with systolic blood pressure and levels of FABP4 (r = 0.331, P < 0.001), fibroblast growth factor 21, homeostasis model assessment of insulin resistance as an insulin resistance index and uric acid, and was negatively correlated with levels of high-density lipoprotein cholesterol and adiponectin. FABP4 concentration was independently associated with FLI after adjustment of age, sex, systolic blood pressure and levels of uric acid, high-density lipoprotein cholesterol, homeostasis model assessment of insulin resistance, adiponectin and fibroblast growth factor 21 in multivariable regression analysis. Logistic regression analysis showed that FABP4 was an independent predictor of MAFLD after adjustment of age, sex, presence of diabetes mellitus, hypertension and dyslipidemia, and levels of uric acid, homeostasis model assessment of insulin resistance, adiponectin and fibroblast growth factor 21.

CONCLUSIONS: FABP4 concentration is independently associated with FLI and is an independent predictor of MAFLD in middle-aged and elderly individuals.

© 2021 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.

Keywords: Adipokine; Fatty liver index; Hepatokine

References

  1. Hamaguchi M, Kojima T, Takeda N, et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005; 143: 722-728. - PubMed
  2. Amarapurkar DN, Hashimoto E, Lesmana LA, et al. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22: 788-793. - PubMed
  3. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015; 62: S47-64. - PubMed
  4. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020; 73: 202-209. - PubMed
  5. Bedogni G, Bellentani S, Miglioli L, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6: 33. - PubMed
  6. Takahashi S, Tanaka M, Higashiura Y, et al. Prediction and validation of nonalcoholic fatty liver disease by fatty liver index in a Japanese population. Endocr J 2021. https://doi.org/10.1507/endocrj.EJ21-0563 - PubMed
  7. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. Nature 2017; 542: 177-185. - PubMed
  8. Furuhashi M, Fucho R, Görgün CZ, et al. Adipocyte/macrophage fatty acid-binding proteins contribute to metabolic deterioration through actions in both macrophages and adipocytes in mice. J Clin Investig 2008; 118: 2640-2650. - PubMed
  9. Furuhashi M, Hotamisligil GS. Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov 2008; 7: 489-503. - PubMed
  10. Furuhashi M. Fatty acid-binding protein 4 in cardiovascular and metabolic diseases. J Atheroscler Thromb 2019; 26: 216-232. - PubMed
  11. Mita T, Furuhashi M, Hiramitsu S, et al. FABP4 is secreted from adipocytes by adenyl cyclase-PKA- and guanylyl cyclase-PKG-dependent lipolytic mechanisms. Obesity 2015; 23: 359-367. - PubMed
  12. Cao H, Sekiya M, Ertunc M, et al. Adipocyte lipid chaperone AP2 is a secreted adipokine regulating hepatic glucose production. Cell Metab 2013; 17: 768-778. - PubMed
  13. Furuhashi M, Fuseya T, Murata M, et al. Local production of fatty acid-binding protein 4 in epicardial/perivascular fat and macrophages is linked to coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2016; 36: 825-834. - PubMed
  14. Fuseya T, Furuhashi M, Matsumoto M, et al. Ectopic fatty acid-binding protein 4 expression in the vascular endothelium is involved in neointima formation after vascular injury. J Am Heart Assoc 2017; 6: e006377. - PubMed
  15. Furuhashi M, Tuncman G, Görgün CZ, et al. Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 2007; 447: 959-965. - PubMed
  16. Burak MF, Inouye KE, White A, et al. Development of a therapeutic monoclonal antibody that targets secreted fatty acid-binding protein aP2 to treat type 2 diabetes. Sci Transl Med 2015; 7: 319ra205. - PubMed
  17. Furuhashi M, Mita T, Moniwa N, et al. Angiotensin II receptor blockers decrease serum concentration of fatty acid-binding protein 4 in patients with hypertension. Hypertens Res 2015; 38: 252-259. - PubMed
  18. Hsu WC, Okeke E, Cheung S, et al. A cross-sectional characterization of insulin resistance by phenotype and insulin clamp in East Asian Americans with type 1 and type 2 diabetes. PLoS One 2011; 6: e28311. - PubMed
  19. Nakamura R, Okura T, Fujioka Y, et al. Serum fatty acid-binding protein 4 (FABP4) concentration is associated with insulin resistance in peripheral tissues. A clinical study. PLoS One 2017; 12: e0179737. - PubMed
  20. Xu A, Wang YU, Xu JY, et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006; 52: 405-413. - PubMed
  21. Ota H, Furuhashi M, Ishimura S, et al. Elevation of fatty acid-binding protein 4 is predisposed by family history of hypertension and contributes to blood pressure elevation. Am J Hypertens 2012; 25: 1124-1130. - PubMed
  22. Ishimura S, Furuhashi M, Watanabe Y, et al. Circulating levels of fatty acid-binding protein family and metabolic phenotype in the general population. PLoS One 2013; 8: e81318. - PubMed
  23. Fuseya T, Furuhashi M, Yuda S, et al. Elevation of circulating fatty acid-binding protein 4 is independently associated with left ventricular diastolic dysfunction in a general population. Cardiovasc Diabetol 2014; 13: 126. - PubMed
  24. Furuhashi M, Omori A, Matsumoto M, et al. Independent link between levels of proprotein convertase Subtilisin/Kexin type 9 and FABP4 in a general population without medication. Am J Cardiol 2016; 118: 198-203. - PubMed
  25. Furuhashi M, Matsumoto M, Murase T, et al. Independent links between plasma xanthine oxidoreductase activity and levels of adipokines. J Diabetes Investig 2019; 10: 1059-1067. - PubMed
  26. Xu A, Tso AWK, Cheung BMY, et al. Circulating adipocyte-fatty acid binding protein levels predict the development of the metabolic syndrome: a 5-year prospective study. Circulation 2007; 115: 1537-1543. - PubMed
  27. Tso AW, Xu A, Sham PC, et al. Serum adipocyte fatty acid binding protein as a new biomarker predicting the development of type 2 diabetes: a 10-year prospective study in a Chinese cohort. Diabetes Care 2007; 30: 2667-2672. - PubMed
  28. Furuhashi M, Yuda S, Muranaka A, et al. Circulating fatty acid-binding protein 4 concentration predicts the progression of carotid atherosclerosis in a general population without medication. Circ J 2018; 82: 1121-1129. - PubMed
  29. Saito N, Furuhashi M, Koyama M, et al. Elevated circulating FABP4 concentration predicts cardiovascular death in a general population: a 12-year prospective study. Sci Rep 2021; 11: 4008. - PubMed
  30. Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992. - PubMed
  31. Nati M, Chung KJ, Chavakis T. The role of innate immune cells in nonalcoholic fatty liver disease. J Innate Immun 2021; 1-11. https://doi.org/10.1159/000518407 - PubMed
  32. Bourebaba N, Marycz K. Hepatic stellate cells role in the course of metabolic disorders development - a molecular overview. Pharmacol Res 2021; 170: 105739. - PubMed
  33. Hu B, Guo Y, Garbacz WG, et al. Fatty acid binding protein-4 (FABP4) is a hypoxia inducible gene that sensitizes mice to liver ischemia/reperfusion injury. J Hepatol 2015; 63: 855-862. - PubMed
  34. Chiyonobu N, Shimada S, Akiyama Y, et al. Fatty Acid Binding Protein 4 (FABP4) overexpression in intratumoral hepatic stellate cells within hepatocellular carcinoma with metabolic risk factors. Am J Pathol 2018; 188: 1213-1224. - PubMed
  35. Thompson KJ, Austin RG, Nazari SS, et al. Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma. Liver Int 2018; 38: 1074-1083. - PubMed
  36. Yamamoto T, Furuhashi M, Sugaya T, et al. Transcriptome and metabolome analyses in exogenous FABP4- and FABP5-treated adipose-derived stem cells. PLoS One 2016; 11: e0167825. - PubMed
  37. Bosquet A, Guaita-Esteruelas S, Saavedra P, et al. Exogenous FABP4 induces endoplasmic reticulum stress in HepG2 liver cells. Atherosclerosis 2016; 249: 191-199. - PubMed
  38. Carnagarin R, Tan K, Adams L, et al. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-a condition associated with heightened sympathetic activation. Int J Mol Sci 2021; 22: 4241. - PubMed
  39. Hyun Koh J, Goo Shin Y, Min Nam S, et al. Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients. Diabetes Care 2009; 32: 147-152. - PubMed
  40. Kim Y-C, Cho Y-K, Lee W-Y, et al. Serum adipocyte-specific fatty acid-binding protein is associated with nonalcoholic fatty liver disease in apparently healthy subjects. J Nutr Biochem 2011; 22: 289-292. - PubMed
  41. Suh J-B, Kim SM, Cho G-J, et al. Serum AFBP levels are elevated in patients with nonalcoholic fatty liver disease. Scand J Gastroenterol 2014; 49: 979-985. - PubMed
  42. Xu Y, Ma X, Pan X, et al. Serum adipocyte fatty acid-binding protein levels: an indicator of non-alcoholic fatty liver disease in Chinese individuals. Liver Int 2019; 39: 568-574. - PubMed
  43. Jeon WS, Park SE, Rhee E-J, et al. Association of serum adipocyte-specific Fatty Acid binding protein with Fatty liver index as a predictive indicator of nonalcoholic Fatty liver disease. Endocrinol Metab 2013; 28: 283-287. - PubMed
  44. Greco D, Kotronen A, Westerbacka J, et al. Gene expression in human NAFLD. Am J Physiol Gastrointest Liver Physiol 2008; 294: G1281-1287. - PubMed
  45. He W, Huang C, Zhang X, et al. Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis. Endocrine 2021; 73: 52-64. - PubMed
  46. Coilly A, Desterke C, Guettier C, et al. FABP4 and MMP9 levels identified as predictive factors for poor prognosis in patients with nonalcoholic fatty liver using data mining approaches and gene expression analysis. Sci Rep 2019; 9: 19785. - PubMed
  47. Hoo RLC, Lee IPC, Zhou MI, et al. Pharmacological inhibition of adipocyte fatty acid binding protein alleviates both acute liver injury and non-alcoholic steatohepatitis in mice. J Hepatol 2013; 58: 358-364. - PubMed
  48. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Investig 2006; 116: 1784-1792. - PubMed
  49. Itoh N. FGF21 as a Hepatokine, Adipokine, and Myokine in metabolism and diseases. Front Endocrinol 2014; 5: 107. - PubMed
  50. Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am J Physiol Endocrinol Metab 2020; 319: E827-E834. - PubMed
  51. Furuhashi M, Matsumoto M, Tanaka M, et al. Plasma xanthine oxidoreductase activity as a novel biomarker of metabolic disorders in a general population. Circ J 2018; 82: 1892-1899. - PubMed
  52. Chen Y-L, Li H, Li S, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study. BMC Gastroenterol 2021; 21: 212. - PubMed
  53. Wong RJ, Cheung R. Trends in the prevalence of metabolic dysfunction-associated fatty liver disease in the United States, 2011-2018. Clin Gastroenterol Hepatol 2021; 2011-2018. - PubMed
  54. Higashiura Y, Furuhashi M, Tanaka M, et al. Elevated fatty liver index is independently associated with new onset of hypertension during a 10-year period in both male and female subjects. J Am Heart Assoc 2021; 10: e021430. - PubMed
  55. Higashiura Y, Furuhashi M, Tanaka M, et al. High level of fatty liver index predicts new onset of diabetes mellitus during a 10-year period in healthy subjects. Sci Rep 2021; 11: 12830. - PubMed
  56. Takahashi S, Tanaka M, Furuhashi M, et al. Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects. Sci Rep 2021; 11: 8606. - PubMed
  57. Furuhashi M, Muranaka A, Yuda S, et al. Independent association of fatty liver index with left ventricular diastolic dysfunction in subjects without medication. Am J Cardiol 2021; 158: 139-146. - PubMed

Publication Types

Grant support